Clinical Trials Logo

Abnormal Glucose Tolerance clinical trials

View clinical trials related to Abnormal Glucose Tolerance.

Filter by:
  • None
  • Page 1

NCT ID: NCT04731272 Not yet recruiting - Diabetes Clinical Trials

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions to preserve β-cell function are crucial for delaying and potentially preventing CFRD development. In this study, we hypothesize that weekly administration of the long-acting glucagon-like peptide-1 (GLP-1) agonist dulaglutide will improve defective early-phase insulin secretion and improve glucose tolerance during a mixed-meal tolerance test.

NCT ID: NCT04490460 Enrolling by invitation - Clinical trials for Abnormal Glucose Tolerance

Effects on Glycemic Control of WBF-0031 in Subjects With Abnormal Glucose Tolerance

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Evaluation of the safety and effects on glycemic control of medical food formulation WBF-0031 in subjects with abnormal glucose control.

NCT ID: NCT01773707 Active, not recruiting - Type 1 Diabetes Clinical Trials

CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1

Start date: March 2013
Phase: Phase 2
Study type: Interventional

The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial. All subjects will receive close monitoring for development of AGT or T1DM. Subjects will receive Abatacept or placebo and close monitoring for development of AGT or T1DM. To assess the safety, efficacy, and mode of action of Abatacept to prevent AGT and T1DM. The primary objective is to determine whether intervention with Abatacept will prevent or delay the development of AGT in at-risk autoantibody positive non-diabetic relatives of patients with T1DM. Secondary outcomes include: the effect of Abatacept on the incidence of T1DM; analyses of C-peptide and other measures from the OGTT; safety and tolerability; and mechanistic outcomes.